neuroinflammation

Contineum Dials Back Plans with $110M IPO to Fund Neuroinflammatory Trials
BioSpace
Fri, 04/5/24 - 11:32 am
Contineum Therapeutics
IPOs
neuroinflammation
Bristol Myers Pays Dragonfly $55M to Bring NK Cells to Neuro Diseases
Xconomy
Mon, 07/6/20 - 10:48 am
Bristol-Meyers Squibb
Dragonfly Therapeutics
multiple sclerosis
MS
neuroinflammation